

Lumito presents at Financial Stockholm on the 21st of October

Lumito AB (publ) ("Lumito" or the "Company") is currently conducting a rights issue, with a subscription period ending on the 30th of October 2025. Lumito's CEO, Sanna Wallenborg, will present the Company, the rights issue, and future plans at Financial Stockholm's event at Hotel Scandic Anglais in Stockholm on the 21st of October 2025.

Financial Stockholm

Date and time: 21st of October 2025, 5:20-8:00 p.m. (Lumito's presentation is at 5:30-5:50 p.m.).

Location: Scandic Anglais, Stockholm.

Register [here](#).

The event will be filmed and made available on the Company's website afterwards.

For details about the ongoing rights issue, click [here](#).

For further information, please contact:

Sanna Wallenborg, CEO Lumito

E-mail: sw@lumito.se

Ph: +4670-870 01 68

About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments

[Lumito presents at Financial Stockholm on the 21st of October](#)